NIDA Funding Strategy for Fiscal Year 2011

Mission

NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction.

This charge has two critical components. The first is the strategic support and conduct of research across a broad range of disciplines. The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction.

Funding Strategy

Funding decisions will be based primarily on programmatic priority of the Institute and scientific merit of the application. NIDA continues to give additional consideration to first-time R01 investigators and Early Stage Investigators (by NIH definition).

Information regarding the FY 2011 NIH Fiscal Policy for Grants can be found at:

• FY 2011 Grant Fiscal Policy: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-11-077.html
• FY 2011 NRSA Stipends: http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-11-067.html

Based on the FY 2011 full-year Continuing Resolution, the National Institute on Drug Abuse (NIDA) has established the following funding policy.

Competing Awards

NIDA may reduce competing awards from IRG recommended levels in order to increase the number of awards issued. Inflation of non-modular awards will be no more than 2%. As for all NIH Institutes, NIDA will implement a 2% increase at all stipend levels for NRSA awards.

Renewal grants should not increase by more than 10% over the prior yearÕs award

Non-Competing Continuations Awards

• Modular continuation awards will be funded at 97% of committed levels, including co-funds. There will be no inflation for future years. This policy does not apply to F's, T's, K's, COOPs and R13s.
• Non-modular continuation awards will be funded at 97% of committed levels, including co-funds. Recurring costs for future years will be increase by 2%. This policy does not apply to F's, T's, K's, COOPs and R13s
• Research training awards (Fs and Ts) will be allowed a 2% increase for stipends only.
• SBIR/STTRs will receive no cuts. Recurring costs for future years will be increased by 2%.

NIDA will continue to support the:

• NIH Pathway to Independence Awards (K99/R00) (http://grants.nih.gov/grants/guide/pa-files/PA-10-063.html) to maintain new and talented NIH-supported independent investigators.